Loading...
•
Jun 30, 2023
Applied Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Applied Therapeutics reported on their progress in advancing programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy in the second quarter of 2023.
Continued to advance programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy.
Efforts will focus on regulatory progress in Galactosemia and SORD Deficiency.
Phase 3 clinical readouts in SORD Deficiency and DbCM are expected in 2H 2023.
Commitment to bring govorestat (AT-007) and caficrestat (AT-001) to patients with devastating diseases in need of treatment remains steadfast.
Applied Therapeutics
Applied Therapeutics
Forward Guidance
The company provided forward-looking statements regarding their plans to request a pre-NDA meeting or submit an NDA or MAA for approval and the anticipated cash runway of the Company.